Koru Medical Systems, Inc. KRMD
We take great care to ensure that the data presented and summarized in this overview for KORU Medical Systems, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding KRMD
View all-
First Light Asset Management, LLC Edina, MN5.04MShares$13.2 Million1.22% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.78MShares$4.67 Million0.0% of portfolio
-
Archon Capital Management LLC Seattle, WA1.05MShares$2.75 Million2.29% of portfolio
-
Meros Investment Management, LP Dallas, TX804KShares$2.11 Million1.03% of portfolio
-
Rbf Capital, LLC San Francisco, CA798KShares$2.09 Million0.12% of portfolio
-
Albion Financial Group705KShares$1.85 Million0.14% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny470KShares$1.23 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA434KShares$1.14 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY405KShares$1.06 Million0.0% of portfolio
-
B. Riley Asset Management, LLC Dallas, TX308KShares$807,6930.42% of portfolio
Latest Institutional Activity in KRMD
Top Purchases
Top Sells
About KRMD
KORU Medical Systems, Inc. designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. It offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company also provides education and training materials to clinicians, patients, and patient advocates. It sells its products through direct sales and medical device distributors, as well as online. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Chester, New York.
Insider Transactions at KRMD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 01
2024
|
Donna French Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,454
+7.14%
|
$10,908
$2.75 P/Share
|
|
Oct 01
2024
|
Shahriar Matin Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,454
+6.9%
|
$10,908
$2.75 P/Share
|
|
Oct 01
2024
|
Edward Wholihan Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,454
+18.66%
|
$10,908
$2.75 P/Share
|
|
Oct 01
2024
|
Robert Cascella Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,454
+7.14%
|
$10,908
$2.75 P/Share
|
|
Oct 01
2024
|
R John Fletcher Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,181
+4.11%
|
$16,362
$2.75 P/Share
|
|
Sep 30
2024
|
Joseph M. Manko Jr. Director |
BUY
Grant, award, or other acquisition
|
Indirect |
5,454
+0.08%
|
-
|
|
Jul 24
2024
|
Joseph M. Manko Jr. Director |
SELL
Other acquisition or disposition
|
Indirect |
721,781
-9.5%
|
-
|
|
Jul 11
2024
|
Joseph M. Manko Jr. Director |
BUY
Grant, award, or other acquisition
|
Indirect |
5,545
+0.07%
|
-
|
|
Jul 11
2024
|
Robert Cascella Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,545
+7.8%
|
$11,090
$2.71 P/Share
|
|
Jul 11
2024
|
R John Fletcher Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,371
+4.38%
|
$16,742
$2.71 P/Share
|
|
Jul 11
2024
|
Donna French Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,545
+7.8%
|
$11,090
$2.71 P/Share
|
|
Jul 11
2024
|
Shahriar Matin Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,545
+7.52%
|
$11,090
$2.71 P/Share
|
|
Jul 11
2024
|
Edward Wholihan Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,545
+23.23%
|
$11,090
$2.71 P/Share
|
|
Mar 31
2024
|
Joseph M. Manko Jr. Director |
BUY
Grant, award, or other acquisition
|
Indirect |
6,329
+0.08%
|
-
|
|
Mar 31
2024
|
R John Fletcher Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,493
+5.16%
|
$18,986
$2.37 P/Share
|
|
Mar 31
2024
|
Donna French Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,329
+9.54%
|
$12,658
$2.37 P/Share
|
|
Mar 31
2024
|
Shahriar Matin Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,329
+9.18%
|
$12,658
$2.37 P/Share
|
|
Mar 31
2024
|
Edward Wholihan Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,329
+33.13%
|
$12,658
$2.37 P/Share
|
|
Mar 31
2024
|
Robert Cascella Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,329
+9.6%
|
$12,658
$2.37 P/Share
|
|
Mar 13
2024
|
Linda M Tharby Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,094
-0.66%
|
$14,188
$2.09 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 174K shares |
|---|---|
| Other acquisition or disposition | 568K shares |
| Open market or private purchase | 146K shares |
| Other acquisition or disposition | 3.35M shares |
|---|---|
| Open market or private sale | 146K shares |
| Payment of exercise price or tax liability | 7.09K shares |